A Pilot Study to Evaluate the Safety of a 3 Weeks Sitagliptin Treatment in HCC Patients Undergoing Liver Resection
Phase of Trial: Phase I
Latest Information Update: 23 Apr 2017
At a glance
- Drugs Sitagliptin (Primary)
- Indications Liver cancer
- Focus Adverse reactions
- Acronyms HCC-DPPIV
- 23 Apr 2017 Trial design along with preclinical data presented at The International Liver Congress 2017
- 11 Feb 2016 Planned End Date changed from 1 Jun 2018 to 1 Jul 2018 as reported by ClinicalTrials.gov record.
- 11 Feb 2016 Planned primary completion date changed from 1 Oct 2017 to 1 Nov 2017 as reported by ClinicalTrials.gov record.